-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ArticleMedicine Guanlan
On October 22, Wanchun Medicine announced that the investigator-initiated prinabulin combined with nivolumab + ipilimumab can treat the third-line relapsed small cells that have failed in previous immune checkpoint inhibitors and platinum-based chemotherapy.
Plenabulin is a potential "first-in-class" immuno-antitumor drug first discovered in the natural marine product Halimide
Regarding the completion of the first patient administration of pranablin in the Phase 2 SCLC clinical trial, the principal investigator of the Rutgers Cancer Institute in New Jersey and medical oncologist Dr.
In this phase 2 study, as many as 26 patients with extensive-stage SCLC who have progressed with at least one platinum-based chemotherapy regimen and immune checkpoint inhibitors with histologically or cytologically confirmed treatment will be enrolled and receive Pranabrin+ Nivolumab + Ipilimumab triple therapy
Reference materials:
[1] The Phase 2 clinical study of Pranabrin combined with nivolumab + ipilimumab in the treatment of third-line relapsed small cell lung cancer patients with previous immune checkpoint inhibitors failed to complete the first patient administration.
(The original text has been deleted)
